Best Immunotherapy doctors: TOP 71 doctors

• Specializes in cancer immunotherapy and targeted therapies.
• Trained in immunooncology at Mount Vernon Cancer Center, London, UK.
• Certified by the European Society of Medical Oncology (ESMO).
• Member of ESMO and European School of Oncology.
• Practices in the United States and Turkey.

• Specializes in cancer immunotherapy using targeted therapies.
• Trained in Turkey and at NATO KFOR Command.
• Member of the Turkish Medical Oncology Association.
• Over 40 publications in cancer research, focusing on immunotherapy.
• Professor at Istanbul Okan University Faculty of Medicine.

• Utilizes checkpoint inhibitors and CAR T-cell therapy for immunotherapy.
• Trained in Turkey and USA, including at MD Anderson Cancer Center.
• Member of the American Society of Clinical Oncology.
• Specializes in immunotherapy for various cancers including lung and breast.
• Completed fellowship in Cancer Institute at Hacettepe University.

• Uses checkpoint inhibitors and monoclonal antibodies in immunotherapy treatments.
• Has international training and practice experience in Turkey.
• Is a member of the European Medical Oncology Association and the American Clinical Oncology Association.
• Has more than 20 years of experience in cancer treatment and immunotherapy.
• Has written over 40 articles on advancements in cancer treatment.

• Uses immune checkpoint inhibitors and CAR T-cell therapy for immunotherapy treatments.
• Received international training in the USA and France in oncology and radiotherapy.
• President of the Society of Oncologists and Radiotherapists in Israel.
• Member of the American Cancer Society and European Society of Oncology.
• Certified by the Israeli Society for Oncology and Radiotherapy.

• Uses checkpoint inhibitors and monoclonal antibodies for immunotherapy treatments.
• Has trained and practiced internationally, including in Turkey.
• Is a member of the European Society for Medical Oncology.
• Was honored with the Oncology Research Award by the Turkish Medical Oncology Association.
• Has written over 20 papers on medical oncology.

• Uses immunotherapy with Keytruda (pembrolizumab) for cancer treatment.
• Completed training in gastrointestinal oncology in London, UK.
• Ranked among the top doctors in Israel.
• Member of prominent oncology organizations.
• Certified in the systemic treatment of digestive system cancers.

• Dr. Ralf Buhl uses personalized immunotherapy for brain tumor treatment.
• He has given lectures in the US and China.
• Dr. Buhl is a member of European medical organizations.
• He holds a Doctor of Medical Sciences degree.
• Dr. Buhl has co-founded a fund for brain tumor research.

• Specializes in biological cancer therapy, including immunotherapy for various cancer types.
• Trained in the UK, Israel, and Georgia.
• Member of the European Society for Medical Oncology and the American Society of Clinical Oncology.
• Authored over 30 articles on cancer treatment.
• Lecturer at Tel Aviv University.

• Dr. Tamar Sapra uses checkpoint inhibitors and monoclonal antibodies for immunotherapy.
• Trained internationally in the United States and Germany.
• Certified by the American Board of Radiology.
• Member of the European Society for Medical Oncology.
• Fluent in English and German.

Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.

• Specializes in adoptive cell transfer and checkpoint inhibitors for immunotherapy.
• Trained in Germany, extensive international collaborations.
• Ranked as a top oncologist in Germany by Focus rating.
• Certified Oncologist, member of the German Cancer Society.

Dr. Manuela Seifert is a top German breast specialist.

Specialty

Dr. Manuela Seifert is a specialist in diagnostics, therapy and aftercare of breast diseases and sonography.

Dr. Seifer applies breast conserving operations as a key treatment method.

Work experience

• Since 2016 – Head of Breast Clinic at Medical Center in Solingen
• 2012-2016 – Breast & senology specialist at Helios Universitätsklinikum Wuppertal
• 2001-2012 – Senior gynecologist and obstetrician in the Gynecology & Obstetrics Department at Klinikverbund St. Antonius und St. Josef GmbH.

Education

• The Medical Faculty of the Heinrich-Heine-University – Degree in general medicine
• Klinikverbund St. Antonius und St. Josef GmbH – Specialty in gynecology and obstetrics.

Dr. Raj is a highly experienced Surgical Oncologist with 19 years of experience and over 50,000 cancer surgeries performed. He is involved in numerous clinical trials and has many international and national publications to his credit. He specializes in Breast and Thoracic Surgical Oncology and serves as a professor for DNB Superspecialty Surgical Oncology and Breast Surgery at the Maharashtra University of Health Sciences. His belief is in "adding life to years" and improving the quality of life, not just adding years to life.

• Specializes in immunotherapy for hematological malignancies.
• Trained in immunology in Germany, extensive international lectures.
• Member of the German Society of Hematology and Medical Oncology.
• Provides remote consultations for immunotherapy second opinions.
• Completed immunology specialization in 1987, senior physician since 2007.

Field of Speciality: Urology
Date of Birth: 1980
School of Medicine:  Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English

Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.

Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot

​

After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments

His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement   Penile Implants , Penile Enhancement , SafeFill and MaleShot  into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.

(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)

​

Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.

​

​

OTHER AREAS OF FOCUS

Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias

​

Membership of Scientific Organizations

Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications

• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en

​

• Uses CAR T-cell therapy, checkpoint inhibitors, and monoclonal antibodies for immunotherapy.
• Trained in Germany, USA, and Switzerland.
• Certified in Hematology and Medical Oncology.
• Member of the American Society of Hematology.
• Ranked top 5% in non-Hodgkin lymphoma treatment outcomes.

This doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.

• Specializes in immune checkpoint inhibitors for cancer-related neurotoxicities.
• Trained in Neurology and Neuro-Oncology in Spain and the USA.
• Founder and past president of the European Association of Neuro-Oncology.
• PhD from Universitat Autónoma de Barcelona, certified in Neurology.
• Emeritus investigator at IDIBAPS, focusing on neuroimmunological research.

One of the best cancer specialists in Europe, educator, and cancer researcher, President of the Central European Cooperative Oncology Group (CECOG).
Has published over 600 scientific papers on cancer treatment.